CytoTronics has acquired Axion BioSystems for an undisclosed amount, marking a significant expansion in the live-cell analysis market. Axion BioSystems, headquartered in Atlanta, Georgia, is known for its suite of live-cell analysis tools, including the Maestro multielectrode array (MEA) system, Maestro Z live-cell analyzer, and Omni imager. These award-winning products offer continuous, noninvasive monitoring of in vitro cell models, supporting research in neurology, cardiology, immunotherapies, and antivirals.
Since its inception with the Maestro MEA system in 2008, Axion BioSystems has grown to employ over 180 individuals worldwide, consistently expanding its offerings to simplify workflows for academic, biotechnology, and pharmaceutical laboratories. Its technology provides real-time, label-free monitoring with powerful software and scalable throughput, accelerating scientific breakthroughs and transforming therapeutic development from discovery to manufacturing.
This acquisition by CytoTronics is a strategic move to enhance its capabilities and product portfolio within the life sciences sector. By integrating Axion BioSystems' advanced live-cell analysis platforms, CytoTronics aims to strengthen its position in critical research areas such as drug discovery, disease mechanism investigation, and therapeutic development. The synergy between CytoTronics' existing operations and Axion's innovative tools is expected to create a more comprehensive offering for researchers and developers globally.
The combination of Axion's expertise in continuous, noninvasive cell monitoring and CytoTronics' broader strategic vision is anticipated to accelerate innovation. This purchase allows CytoTronics to leverage Axion's established market presence and its user-friendly, high-throughput solutions, expanding reach into new customer segments and applications.
The newly combined entity is poised to deliver enhanced solutions for cell analysis, driving progress in biomedical research and therapeutic development. This integration is expected to foster continued innovation, providing scientists with more powerful and efficient tools to advance their understanding of cellular processes and develop new treatments.